{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Branch+II&page=90", "query": { "intervention": "Branch II", "page": 90 }, "page_size": 10 }, "pagination": { "page": 90, "page_size": 10, "total_count": 4767, "total_pages": 477, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Branch+II&page=91&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Branch+II&page=89&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T23:11:17.461Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02063698", "title": "Auranofin in Decreasing Pain in Patients With Paclitaxel-Induced Pain Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pain" ], "interventions": [ { "name": "auranofin", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2014-02-19", "completion_date": "2016-11-11", "has_results": true, "last_update_posted_date": "2019-04-23", "last_synced_at": "2026-11-06T23:11:17.461Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02063698" }, { "nct_id": "NCT01761747", "title": "Ponatinib for Squamous Cell Lung and Head and Neck Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer, Head and Neck Cancer" ], "interventions": [ { "name": "ponatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2013-01", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2014-12-23", "last_synced_at": "2026-11-06T23:11:17.461Z", "location_count": 4, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01761747" }, { "nct_id": "NCT03719326", "title": "A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "TNBC - Triple-Negative Breast Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "Etrumadenant", "type": "DRUG" }, { "name": "IPI-549", "type": "DRUG" }, { "name": "Pegylated liposomal doxorubicin (PLD)", "type": "DRUG" }, { "name": "nanoparticle albumin-bound paclitaxel (NP)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 35, "start_date": "2018-10-15", "completion_date": "2021-07-02", "has_results": false, "last_update_posted_date": "2024-05-24", "last_synced_at": "2026-11-06T23:11:17.461Z", "location_count": 20, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 16 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03719326" }, { "nct_id": "NCT02746393", "title": "SFGH Health Advocates Stage II Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Conditions Influencing Health Status", "Social Determinants of Health" ], "interventions": [ { "name": "Health Advocates Program", "type": "OTHER" }, { "name": "211 Information Sheet", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1278, "start_date": "2016-07", "completion_date": "2020-07", "has_results": false, "last_update_posted_date": "2020-10-06", "last_synced_at": "2026-11-06T23:11:17.461Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02746393" }, { "nct_id": "NCT03680092", "title": "Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "GVHD", "Hematologic Neoplasms" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "abatacept", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dimitrios Tzachanis, MD PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2019-11-26", "completion_date": "2023-06-15", "has_results": true, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-11-06T23:11:17.461Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03680092" }, { "nct_id": "NCT02604511", "title": "Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Waldenstrom's Macroglobulinemia" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2016-01", "completion_date": "2022-11-01", "has_results": true, "last_update_posted_date": "2022-12-07", "last_synced_at": "2026-11-06T23:11:17.461Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02604511" }, { "nct_id": "NCT02192333", "title": "Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Carcinoma", "Cancer Survivor", "Depression", "Fatigue", "Leukemia", "Lymphoma", "Malignant Bone Neoplasm", "Malignant Digestive System Neoplasm", "Malignant Female Reproductive System Neoplasm", "Malignant Male Reproductive System Neoplasm", "Pain", "Sleep Disorder", "Soft Tissue Sarcoma" ], "interventions": [ { "name": "Management of Therapy Complications", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Telephone-Based Intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "PROCEDURE", "OTHER", "BEHAVIORAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 390, "start_date": "2015-08-03", "completion_date": "2019-12-31", "has_results": false, "last_update_posted_date": "2020-10-09", "last_synced_at": "2026-11-06T23:11:17.461Z", "location_count": 6, "location_summary": "Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02192333" }, { "nct_id": "NCT07902921", "title": "STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "NSCLC", "Non-Small Cell Lung Cancer", "Lung Cancer", "Prostate Cancer", "Thymic Epithelial Tumors", "TETs", "Thymic Carcinomas", "Thymomas", "Metastatic Castrate-resistant Prostate Cancer", "mCRPC" ], "interventions": [ { "name": "STAR0602", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 67, "start_date": "2026-11-11", "completion_date": "2030-06-30", "has_results": false, "last_update_posted_date": "2026-11-06", "last_synced_at": "2026-11-06T23:11:17.461Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07902921" }, { "nct_id": "NCT04993313", "title": "Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anatomic Stage 0 Breast Cancer AJCC v8", "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage 0 Breast Cancer AJCC v8", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Breast Carcinoma" ], "interventions": [ { "name": "Counseling", "type": "OTHER" }, { "name": "Educational Intervention", "type": "OTHER" }, { "name": "Questionnaire", "type": "BEHAVIORAL" } ], "intervention_types": [ "OTHER", "BEHAVIORAL" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2022-03-18", "completion_date": "2027-02-28", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-11-06T23:11:17.461Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04993313" }, { "nct_id": "NCT05797246", "title": "Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Respiratory Tract Diseases", "Neoplasms", "Neoplasms by Histologic Type", "Neoplasms, Glandular and Epithelial", "Neoplasms, Squamous Cell", "Tumor Virus Infections", "Infections", "Virus Diseases", "DNA Virus Infections", "Pathologic Processes", "Disease Attributes", "Recurrence", "Papilloma", "Respiratory Tract Infections", "Papillomavirus Infections" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 21, "start_date": "2023-08-02", "completion_date": "2029-01-01", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-06T23:11:17.461Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05797246" } ] }